receptor

(redirected from Nicotinic receptor)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.
See: receiver
Mentioned in ?
References in periodicals archive ?
ABT-126 potentiates the action of the alpha-7 nicotinic receptor, which is expressed both pre- and postsynaptically.
Washington, November 9 ( ANI ): Inactivation of a specific sub-class of nicotinic receptors may be an effective strategy to help smokers quit without feeling anxious, US researchers suggest.
Male Wistar rats (300 - 350 g; Charles River, Barcelona, Spain) were used to obtain small intestine (ileum) fragments, for testing muscarinic receptor antagonism, and diaphragm/phrenic-nerve preparations, for testing nicotinic receptor antagonism and acetylcholinesterase inhibition.
In this case, the past dates back to the late 1980s, when researchers began to realize the breadth of the brain's inventory of nicotinic receptors.
Nicotinic receptor stimulation leads to tachycardia, hypertension, mydriasis, fasciculations and muscle weakness, as well as respiratory failure.
a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics(TM), has initiated a Phase I clinical trial of TC-5619, a novel small molecule that modulates the activity of the neuronal nicotinic receptor (NNR) subtype known as alpha7.
Long-term ethanol treatment elicits changes in nicotinic receptor binding in only a few brain regions.
brain and binds to a nicotinic receptor which activates the reward pathway in
Other new and potent pain relievers now being tested include drugs that act on a class of nicotinic receptor (the receptor that reacts to tobacco) and a drug that selectively blocks a gate that opens when a pain nerve cell fires an impulse.
Suven Life Sciences for NCE for treatment of major depressive disorder declared that its drug discovery portfolio has stretched out into several new therapeutic areas such as Major Depressive Disorder (MDD), Obesity and Pain through Neuronal Nicotinic Receptor modulators which resulted in the grant of one (1) product patent from USA (8653071), corresponding to the New Chemical Entity (NCE) for the treatment of disorders associated with Neurodegenerative diseases and this Patent is valid through 2030.
Fang Liu, Senior Scientist in CAMH's Campbell Family Mental Health Research Institute and Professor in the Department of Psychiatry at the University of Toronto and her team initially found that nicotine exposure can enhance binding between two types of brain receptors - a nicotinic receptor and a glutamate receptor.
Findings from these collaborative studies were recently presented at the Society for Neuroscience Annual Meeting in a study titled "AT-1001, a Highly Selective alpha3beta4 nicotinic Receptor Antagonist is Effective in Blocking Place Preference, Behavioral Sensitization, and Withdrawal Effects of Various Drugs of Abuse.